A Phase 1 Study of Substance P-Saporin in Terminal Cancer Patients With Intractable Pain
Interventional
Primary Purpose: Treatment
Number of participants with adverse events using the National Cancer Institute's Common Terminology Criteria for Adverse Events Version 4 as a measure of safety and tolerability in subjects with chronic pain refractory to opioid therapy.
Patients will be followed weekly for 8 weeks, then monthly for up to 6 months.
Yes
United States: Food and Drug Administration
SP-SAP
NCT01875432
Name | Location |
---|---|
University of Texas Southwestern Medical Center | Dallas, Texas |